Try our Advanced Search for more refined results
Life Sciences - February, 2021
288 articles
- House Approves Biden's $1.9T Pandemic Relief Package
- DOJ Suffers Rare Rejection Of Late FCA Case Takeover
- 1st Circ. Upholds 3 Ex-NECC Workers' Drug Fraud Convictions
- Arbor Hits FDA With Suit Over Neurological Drug
- Harvest Health Unit Hit With Age, Race Discrimination Suit
- Walgreens Relieved Of Claims It Mislabeled Infant Pain Med
- Bristol Myers, Citigroup Can't Shake NJ Pollution Suit
- Novo Nordisk Hit With Bias Suit Over 'Sexist Work Culture'
- 3rd Circ. Preview: AT&T Leads Packed March Schedule
- Gov't Contracts Of The Month: Vaccines, Post Office Revamp
- 4 Paths The Justices Could Take In Arthrex
- Alleged Chinese Agent At Stanford Denies Obstruction, Fraud
- Cos. Should Back Up Sensory Advertising Claims With Data
- Fla. Bills Seek Cannabis Legalization, Taxation
- Chemours Board Sued In Del. For Undisclosed Toxic Tabs
- FDA Panel Clears J&J COVID-19 Vaccine For Emergency Use
- Baxter Settles Investor Suit Over Forex Accounting Controls
- What Biden's Ethics Pledge Means For Gov't Revolving Door
- March Trial Set For Patent Battle Over Glaucoma Treatment
- UK Litigation Roundup: Here's What You Missed In London
- Meet The Supreme Court Heavyweights Arguing Arthrex
- Investors Maintain Nerve Repair Co. Axogen Lied In SEC Docs
- Small Odds Humira Patents All Invalid 'Worries' 7th Circ
- Mallinckrodt Wins Tussle Over Ch. 11 Deadline Extension
- Judge Refuses To End Sterigenics' Suit Against Ga. County
- Tribunal Upholds CMA's Antidepressant Market Rigging Fine
- Sparks Fly As Sen. Committee Mulls Top Biden Health Picks
- Insurers Can't Be Charged For Medical Pot, Mass. Court Says
- Punishing Bar Exam Policies On Menstrual Products Must Go
- The Supreme Court PTAB Cases That Came Before Arthrex
- Cell-Based Drugmaker Cellarity Nabs $123M From Investors
- Deals Rumor Mill: Toast, Sportradar, Victoria's Secret
- Covington, Skadden Rep Merck's $1.9B Pandion Buy
- As McKinsey Is Dragged Into MDL, Fresh Atty Tensions Arise
- Rosen to Rep Biogen Investors In Drug Trial Fraud Suit
- Nevro Lobs New Suit At Boston Scientific Over Spine Pain IP
- Justices Urged To Fix Fed. Circ. 'Paradox' In Heart Drug Case
- Two Mo. Pot Cos. Win Licenses In Appeal Over Scoring Flaws
- Takeaways From DOJ Fraud Section's Pandemic Year
- Rakoff Hits Ex-MiMedx Exec With 1 Year For Fraud Scheme
- Medtronic Recalls Stent System After Trial Patient Death
- Moderna Asks Fed. Circ. To Undo Drug-Delivery Patent Ruling
- EPA Hazardous Pharma Waste Rule Has Wide Reach
- Zofran Birth Defect MDL Finally Heading For Trial In Fall
- It's Time For Law Firms To Start Loving And Leveraging Data
- Cahill Gordon, Paul Weiss Shape $12B ICON-PRA Health Deal
- Biden Orders Sweeping Review Of Crucial Supply Chains
- Should An Atty Lead HHS? Lawmakers Debate Pros And Cons
- Unaddressed Split On FCA Objectivity May Spur Settlements
- Illumina Wants 'Entirely Derivative' Antitrust Suit Paused
- Fed. Circ. Tailors Arguments After Teva Skinny Label Outcry
- Justices Told Assignor Estoppel Is 'Uncommonly Lawless'
- 7th Circ. To Crawl Into Humira 'Patent Thicket' Dispute
- Unrepentant Ex-MiMedx CEO Gets 1 Year For Revenue Fraud
- Keys To Protecting Clients During Law Firm Dissolution
- AdventHealth's Fraud Claim Over $57M PPE Deal Advanced
- Pa. Public Housing Agency Must Create Medical Pot Policy
- Coronavirus Regulations: A State-By-State Week In Review
- 10th Circ. Ruling Bolsters Medical Device Preemption Defense
- J&J Reserves $4B For Talc Verdict, Expenses
- Del. Justices Reverse Express Scripts' $82M Trial Loss
- Wife Can't Blame Husband's Co. For Her COVID-19 Infection
- 3 Developments As America's Virus Death Toll Hits 500,000
- Walmart Says DOJ's 'Sensationalist' Opioid Suit Rings Hollow
- Atty Contests Legal Lender's Entry In $350M Shire Fee Row
- Mallinckrodt Ch. 11 Plan Lacks Support For Now, Lenders Say
- Va. Corrections Dept. Can't Escape Body Scan Sex-Bias Suit
- EPA Takes Action To Address PFAS In Drinking Water
- Allergan Patents Spared From PTAB Review In Settlement
- NY AG Opioid Trial Gets March Start After COVID-19 Delays
- SD Pot Advocates Pitch Compromise Medical Marijuana Bill
- How Case Management Orders Can Support New Attorneys
- Justices Reject FCA Liability Requirement Case
- High Court Ruling May Be A Boon For Benefits Access
- Biden Stacking Health Team With Vets Of BigLaw, AG Offices
- Companies Beef Up Risk Disclosures As Biden Era Begins
- EU Clears Varian's $16.4B Sale To Siemens Unit With Fixes
- Baby Formula Device Claims Get Tossed By NY Federal Judge
- 3 Things To Know About FDA's Evolving Drug Inspections
- WB Mason 'Preyed' On Buyers With Fake 3M Masks, Suit Says
- Botox Rival Can Stay On Market Following Allergan Deal
- Health Hires: Hogan Lovells, McGuireWoods
- 2 Firms Tapped To Lead Teva Intrauterine Device MDL
- Bleichmar Fonti Wants To Retake Lead In Endo Investor Suit
- Courts, FTC May Differ On Sponsored Product Reviews
- An In-House Counsel's Guide To Better Work Management
- UK Litigation Roundup: Here's What You Missed In London
- Bayer's $650M PCB Deal Hits Snag Over Extra Funds Window
- Calif. Appeals Court Upholds Judgment In Nerve Damage Case
- NJ Lab Sues Supplier Over False COVID-19 Test Results
- NJ Medical Pot Hopefuls Lose Challenge Over Technical Woes
- 'Opioid Baby' Claims Better Suited For Own Cases, Attys Say
- Mallinckrodt Says Competitor Unlawfully Recruited Employees
- Biologics Face Tougher Patent Scrutiny After Amgen Ruling
- Coronavirus Litigation: The Week In Review
- Drug Database Provider Wins Challenge To OTC Label Change
- Fed. Circ. Says PTAB Wrongly Upheld Cancer Detection Patent
- Genetic Engineering And The Endangered Species Act
- Energy Distributor Sells Chemicals Biz To PE Firm For $570M
- US Cos. Must Prepare For EU Carbon Tax On Imports
- Minn. Cannabis Legalization, Tax Bill Passes House Panel
- How The Pandemic Is Shaping Patent Trials In District Courts
- Justices Should Weigh In On FCA Objective Falsity Standard
- Avoiding Materially Adverse Conflicts After New ABA Opinion
- Deals Rumor Mill: SpaceX, Marqeta, Aerion
- ViSalus Can't Get Trial Redo In $925M Robocall Suit
- Fee Award Reversed In Fla. Medical Marijuana Rule Challenge
- OptumRx Worker Says Turning Down Exec Hurt Her Career
- HHS Assails Eli Lilly's Bid To Halt Drug Discount Rule
- Ex-Theranos CEO Holmes Pans 'Luxurious Lifestyle' Evidence
- Sackler Family Can't Keep Names Of Its Businesses Secret
- Sport Supplement Exec Gets 1 Year For Illicit Steroid Sales
- Coronavirus Regulations: A State-By-State Week In Review
- McKesson Whistleblowers' Opioid FCA Suit Sunk By Escobar
- Stimwave Founder Can't Get Rethink Of Legal Fee Denial
- Inovio Must Face Trimmed Investor Claims Over Virus Vaccine
- McKinsey's Opioid Woes Far From Over Despite $600M Deals
- Parents Ask Judge To Rethink Cert. Denial For 'Opioid Babies'
- Fed. Circ. Grants Last-Minute Pause Of ITC's Botox Rival Ban
- Full Fed. Circ. Won't Rethink Ruling UT Isn't Immune From IPR
- Bristol Myers, Sanofi To Appeal $834M Hawaii Order On Plavix
- Fed. Circ. Won't Revive Generics' Bid To Ax Takeda Patent
- Ex-Vitamin Shoppe CFO Sues For At Least $1.4M In Benefits
- Biomet Seeks Judgment, New Trial In $3.5M Implant Suit
- US Legal System Can Benefit From Nonlawyer Ownership
- FDA Hammers Drugmaker's 'Dangerous' Opioid Promos
- Curaleaf Beats Investors' Stock-Drop Suit Over CBD Legality
- Robbins Geller To Lead Sorrento COVID-19 Class Action
- BMS Accuses Teva Of Infringing Eliquis Blood Thinner Patent
- Royal Mail Settles Antitrust Suit With Medical Testing Co.
- 7 False Claims Act Enforcement Trends To Watch
- Untimely Claims Trimmed From Mich. Medical Pot Raid Suit
- Sandoz Tells Justices Amgen Ruling 'Guts' Patent System
- What Life Sci Attys Think Of Biden's Pace Choosing FDA Boss
- CBD Co. Says Rival Unlawfully Using Its Own Trademark
- Judge Tosses Suit Over Pot Testing Machines
- China Asks 2nd Circ. To Argue For Vitamin C Exporters Again
- Cannabis Bill Roundup: Battle Over SD Medical Takes Shape
- Shoe Insert Co. Accuses Rival Of Bad-Mouthing It In Emails
- Robbins Geller's Money Experts Clinch $1.2B Valeant Deal
- Fed. Circ. Judge 'Baffled' By Mylan Position In PTAB Appeal
- Sorin Group Granted Win In Heart Valve Death Suit
- Pa. Water Utility Says DuPont Illegally Transferred PFAS Biz
- 3 Drug Pricing Strategy Considerations Under Biden Admin.
- Key Deliverables For SPAC Parties Amid Growth Trend
- FDA Warns 11 E-Cig Sellers Over Unauthorized Products
- Risk Allocation For Drug And Device Cos. And Their Suppliers
- UK Litigation Roundup: Here's What You Missed In London
- Gilead, Bristol-Myers Say Direct Buyers Antitrust Suit Too Late
- US Pays Pfizer, Moderna $3.7B For 200M More Vaccine Doses
- Fed. Circ. Says Amgen's Repatha Patents Are Too Expansive
- ADHD Drug Buyer May Need To Arbitrate Antitrust Claims
- Coronavirus Litigation: The Week In Review
- Calif. Man Can't Recover Confiscated Pot, Despite Court Order
- PTAB Grills Mylan And Merck In Diabetes Drug IP Battle
- Miss. Mayor Says Advocate Can't Argue For Medical Pot
- Calif. Biotech Firm Settles SEC's COVID-19 Blood Test Claims
- Merck Sues To Block Inventia's Generic Diabetes Drug
- GAO Says Drug Test Deal Debrief Can't Extend Protest Period
- Building A Law Firm Knowledge Bank For Thought Leadership
- Blue Cross Units, CVS Want Drug Pricing Suits Combined
- What The Biden Presidency Means For Class Actions
- Del. Justices Affirm AstraZeneca Win In Lifted-Data Suit
- Cannabis Co. Insurer Says Faulty Pump Caused $1.5M Fire
- Medtronic Skirted Spine Device FDA Review, 9th Circ. Told
- GAO Signs Off On VA's Medical Supply Contract Awards
- Teva 'Not Optimistic' About Sealing $23B Opioid Deal Soon
- 7th Circ. Asked To Revive Safeway Drug Price Suit
- FDA Warns Mexican Co. Over Hand Sanitizer Strength
- Tribes Insist On Hand In Mallinckrodt Ch. 11 Mediation
- J&J Seeks To Block Alcon's Eye Surgery Laser Product
- PTAB Wipes Out Rembrandt's Drug Testing Patent On Remand
- Data Compliance Issues For Cos. Making, Using Vaccine Apps
- Genentech Wins Toss Of Employee's 401(k) Suit
- Blank-Check Merger Values Genomic, Patient Data Biz At $2B
- Let's Emerge From The Pandemic As Legal Innovators
- SD Gov. Noem To Delay Medical Pot Rollout By A Year
- Indivior Investor Wants OK For $2M Deal In Suboxone Dispute
- EU Accepts Aspen Offer To Slash Prices On Cancer Drugs
- Greenberg Traurig Adds Top Becton Dickinson Atty In NJ
- Teva-Centric Price-Fix Case Likely To Lose Bellwether Status
- AbbVie, Others Move To End Generic Bystolic Antitrust Claims
- Pfizer Says It's Immune From Vaccine Testing IP Claims
- 3rd Circ. Won't Give Fresenius Another Look At Drug Claim
- Fresenius To Pay $50M For Impeding FDA Investigation
- Celgene Sues Dr. Reddy's To Block Cancer Drug Generic
- Kirkland, Wilson Sonsini Guide Deal Forming $1.3B Biotech
- Abbott Labs Ducks Ex-Worker's ERISA Suit Over Stolen $245K
- Ex-Theranos COO's Fraud Trial Moved To January 2022
- Texas Atty Arrested On Telephone Harassment Charge
- Ex-Client Fights To Revive Botched IUD Malpractice Case
- Coronavirus Regulations: A State-By-State Week In Review
- Anticipating Predictive Analytics' Potential Uses In Litigation
- Fed. Circ. Panel Walks Back $235M Skinny Label Ruling
- Novelion Therapeutics Seeks Ch. 15 To Wind Up Liquidation
- Catalent Hit With Patent Suit Over Epilepsy Drug Vimpat
- One Of Trump Admin.'s Top Health Attys Talks Enforcement
- Bumble Upsizes IPO As More Companies Join Pipeline
- Dechert Picks Up IP Partner From Lathrop
- Winston & Strawn Hires Appellate Partner For DC Office
- Whistleblower Gets $3.6M In FCA Deal With Roche, Humana
- Claim Clipped From Cardinal Investors' Suit Over Opioids
- 8th Circ. Won't Revive Suit Over Teva's ParaGard Risks
- Biotech Consultant Hit With Insider Trading Charges
- This Black History Month, Law Firms Should Challenge Norms
- Del. Justices Reject Meso's Bouchard-Related Bias Claims
- Baker Botts Lands Bankruptcy Pro From Greenberg Traurig
- CEO Ken Frazier, Once GC, To Retire From Merck
- Astellas Gets Scientists Cut From Stem Cell Patent After Trial
- Judge Says Inventors Would 'Radically Alter' Tech's PTAB Suit
- 5th Circ. Won't Revive Claims Tying Generic Drugs To Disease
- Fla. Biz Owner Pleads Out Of $400M Health Fraud Case
- Lead Plaintiff Booted From Endo Suit Over 97-Second Lag
- J&J Wins Settlement In Counterfeit Device Row
- Acthar Claimants Hit Skadden For Mallinckrodt Ch. 11 Role
- Bipartisan Senate Bill To Spur Marijuana Research Is Back
- Cannabis Bill Roundup: Va. On Track To OK Recreational Pot
- Exec Says Johnson & Johnson Cut His Job After Surgery
- 9th Circ. Won't Revive Breast Implant Suits Against J&J Unit
- Key FCA Developments From 2020 And What To Expect Next
- A Look At Factors Influencing Medical Device Approval Speed
- Fresenius Lost Chance To Appeal Antitrust Suit, 3rd Circ. Told
- Goodwin-Led Gene Therapy Co. Nabs $150M Via PIPE
- Health Hires: GrayRobinson, MiraMed, AngioDynamics
- Judges On Race
- Law Firm Penalties On Departing Partners Just Got Riskier
- Walmart Loses Bid To Short-Circuit Feds' Opioid Suit
- J&J Seeks Emergency Approval For 1-Shot COVID-19 Vaccine
- McKinsey Deal Renews Friction Among AGs And Opioid Attys
- Bayer's $2B Deal May Not Spell The End For Roundup
- No Thanks, EpiPen Buyers Tell Judge After Trial Delay Invite
- Coronavirus Litigation: The Week In Review
- Coalition Says Bayh-Dole Not For Cutting Drug Costs
- Sana's Smash IPO Tops Biotech Trio Raising $811M Combined
- Period App Shared Health Data With Advertisers, User Says
- CytoDyn Panel Seeks To Reverse $14M Directors Award
- Former Patients Say Rockefeller U. Knew About Sex Abuse
- Litigation Funder Wants Cut Of $350M Shire Deal
- Keller Lenkner Hires Former Aide To Texas AG, White House
- More Senior Staff Accuse UnitedHealth Unit Of No-Poach Plot
- NJ Case Has Lessons On Arbitration Clauses In Atty Retainers
- McKinsey To Pay $573M To Settle Opioid Marketing Claims
- Former Fla. Professor Charged With Fraud, Hiding China Ties
- Covidien Tells Panel That Judge Garbled Patent Case Verdict
- Dollar General Inks $1.8M Deal In Infant Drug False Ad Suit
- Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling
- Biotech Co. Can't Hide DNA Program Info In NJ Murder Case
- Coughlin Duffy Group Jumps To Schenck Price
- Tips For Protecting Privilege When Working With Outside PR
- Senate Panel OKs Commerce Nominee Despite Huawei Doubts
- 3 Procurement Priorities For Law Firms In Uncertain Times
- Bayer Inks $2B Deal To Cover Future Roundup Cancer Claims
- Teva Aims To Revoke IP For BMS Blockbuster Blood Thinner
- 5 Firms Aid As Jazz Pays $7.2B For Rare Disease Drugmaker
- Par Pharma Abusing FDA Process To Foil Rivals, Amneal Says
- Quest Diagnostics Defeats Fired Worker's Disability Bias Suit
- SEC Nabs Partial Win Against Ex-Biotech Executives
- Humira Buyers Say AbbVie 'Contorting' Actavis At 7th Circ.
- Final OK On $1.2B Valeant Deal Earns Robbins Geller $157M
- Investors Seek Class Cert. In Humira Marketing Suit
- NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug
- Structuring Protein-Specific Life Science Partnerships
- Okla. Worker Fired For THC Test Can't Claim Discrimination
- NJ Court Wary Of Medical Pot Hopefuls' Claims Of Tech Glitch
- FDA Warns Sites Over Malaria Drug COVID-19 Claims
- 4th Circ. Revives Bayer's Yearslong 'Flanax' Trademark Fight
- Coronavirus Regulations: A State-By-State Week In Review
- Examining EPO's Strict Approach To AI Patent Disclosure
- UK Is Proof Nonlawyer Ownership Threatens Legal Profession
- Minn. Bill Seeks To Legalize, Tax Recreational Marijuana
- Judge Invalidates Changes To NM Medical Cannabis Rules
- Fed. Circ. Affirms Illumina PTAB Wins Axing Columbia DNA IP
- Consulting Co. McKinsey Sued For Promoting OxyContin
- PhRMA Slams 'Extreme' Call To Strip COVID-19 Patents
- CBD Industry Awaits Action From New Dem-Led Congress
- 'Opioid Babies' Can't Get Class Certification In MDL
- Idaho Lawmakers Push To Make Legal Pot Unconstitutional
- HIG Seeks To Bar Refiling Of False Claims Act Case
- GSK Blasts Teva's Rehearing Bid In $235M Verdict Fight
- Purdue Sues In Ch. 11 To Access $3.3B Insurance Funds
- Blitz Of Biotechs Join Crowded IPO Lineup To Start February
- Bio-Rad's $35M IP Win Tainted By Falsehoods, 10X Says
- Microsoft Can't Apportion Sales Tax, Mass. Justices Told
- FDA Says 30 Websites Shuttered Over Illegal Opioid Sales
- Feds Agree To Push Back Drug Rebate Rule
- Remote Bar Exams Pose New Learning Disability Challenges
- WTO Leaders Call For Unity, Relaxed Vaccine Restrictions
- Cooley, Mintz Levin Craft $3.05B Deal For Drug Developer